Citigroup Inc. Has $5.54 Million Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Citigroup Inc. grew its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 66.6% in the third quarter, HoldingsChannel.com reports. The fund owned 76,772 shares of the company’s stock after buying an additional 30,677 shares during the quarter. Citigroup Inc.’s holdings in Prestige Consumer Healthcare were worth $5,535,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Evergreen Capital Management LLC raised its position in Prestige Consumer Healthcare by 5.4% in the 2nd quarter. Evergreen Capital Management LLC now owns 3,143 shares of the company’s stock valued at $216,000 after purchasing an additional 160 shares during the last quarter. Miller Howard Investments Inc. NY increased its stake in shares of Prestige Consumer Healthcare by 2.2% in the second quarter. Miller Howard Investments Inc. NY now owns 7,762 shares of the company’s stock valued at $534,000 after buying an additional 165 shares in the last quarter. OLD National Bancorp IN raised its holdings in shares of Prestige Consumer Healthcare by 4.4% in the third quarter. OLD National Bancorp IN now owns 3,974 shares of the company’s stock valued at $287,000 after buying an additional 168 shares during the last quarter. Huntington National Bank lifted its position in Prestige Consumer Healthcare by 39.9% during the 3rd quarter. Huntington National Bank now owns 635 shares of the company’s stock worth $46,000 after buying an additional 181 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in Prestige Consumer Healthcare by 80.6% during the 1st quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock worth $33,000 after acquiring an additional 208 shares during the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Prestige Consumer Healthcare

In other news, EVP Adel Mekhail sold 9,063 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total value of $743,166.00. Following the sale, the executive vice president now directly owns 18,365 shares in the company, valued at $1,505,930. This trade represents a 33.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Ronald M. Lombardi sold 10,875 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the transaction, the chief executive officer now owns 320,952 shares of the company’s stock, valued at $26,510,635.20. The trade was a 3.28 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock worth $3,187,300 in the last three months. Insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE:PBH opened at $84.77 on Monday. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. Prestige Consumer Healthcare Inc. has a 1-year low of $56.61 and a 1-year high of $86.36. The stock has a market capitalization of $4.19 billion, a P/E ratio of 20.63, a P/E/G ratio of 2.38 and a beta of 0.47. The business has a 50-day moving average price of $75.41 and a two-hundred day moving average price of $71.19.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The business had revenue of $283.79 million during the quarter, compared to the consensus estimate of $282.09 million. During the same period in the previous year, the firm posted $1.07 earnings per share. Prestige Consumer Healthcare’s revenue for the quarter was down .9% compared to the same quarter last year. Equities analysts predict that Prestige Consumer Healthcare Inc. will post 4.44 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. DA Davidson reaffirmed a “buy” rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Jefferies Financial Group restated a “hold” rating and issued a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. One equities research analyst has rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $83.67.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.